Search Results - "Demidov, L."

Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial by Dummer, R., Gyorki, D. E., Hyngstrom, J., Berger, A. C., Conry, R., Demidov, L., Sharma, A., Treichel, S. A., Radcliffe, H., Gorski, K. S., Anderson, A., Chan, E., Faries, M., Ross, M. I.

“…Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-based intralesional oncolytic immunotherapy approved for the treatment of unresectable…”
Get full text

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma by Robert, C., Lewis, K.D., Gutzmer, R., Stroyakovskiy, D., Gogas, H., Protsenko, S., Pereira, R.P., Eigentler, T., Rutkowski, P., Demidov, L., Caro, I., Forbes, H., Shah, K., Yan, Y., Li, H., McArthur, G.A., Ascierto, P.A.

“…The phase III IMspire150 study (NCT02908672) demonstrated significantly improved progression-free survival (PFS) with atezolizumab, vemurafenib, and…”
Get full text

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study by Schadendorf, D., Amonkar, M.M., Milhem, M., Grotzinger, K., Demidov, L.V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J.C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F.S., Patel, K., Casey, M., Robert, C.

“…In a randomized phase III study, trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600…”
Get full text

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine by Grob, J.-J., Amonkar, M.M., Martin-Algarra, S., Demidov, L.V., Goodman, V., Grotzinger, K., Haney, P., Kämpgen, E., Karaszewska, B., Mauch, C., Miller, W.H., Millward, M., Mirakhur, B., Rutkowski, P., Chiarion-Sileni, V., Swann, S., Hauschild, A.

“…In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95%…”
Get full text

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study by Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., Rooney, I., Voulgari, A., Troutman, S., Pitcher, B., Guo, Y., Yan, Y., Castro, M., Mulla, S., Flaherty, K., Arance, A.

“…Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether…”
Get full text

On the Measurements of Full-Disk Longitudinal Magnetograms at Huairou Solar Observing Station by Demidov, M. L., Wang, X. F., Wang, D. G., Deng, Y. Y.

“…Reliable information on the distribution of magnetic fields across the whole surface of the Sun is urgently needed to predict conditions in the solar corona,…”
Get full text

Melanoma with brain metastases: Experience of immunotherapy in a single center by Naskhletashvili, D.R., Demidov, L.V., Bekyashev, A.H., Aloshin, V.A., Prozorenko, E.V.

Get full text

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments by Kandolf Sekulovic, L, Peris, K, Hauschild, A, Stratigos, A, Grob, J.-J, Nathan, P, Dummer, R, Forsea, A.-M, Hoeller, C, Gogas, H, Demidov, L, Lebbe, C, Blank, C, Olah, J, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Hansson, J, Rutkowski, P, Krajsova, I, Bylaite-Bucinskiene, M, Zalaudek, I, Maric-Brozic, J, Babovic, N, Banjin, M, Putnik, K, Weinlich, G, Todorovic, V, Kirov, K, Ocvirk, J, Zhukavets, A, Kukushkina, M, De La Cruz Merino, L, Ymeri, A, Risteski, M, Garbe, C

“…Abstract Background Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among…”
Get full text

Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma by Plummer, R, Lorigan, P, Brown, E, Zaucha, R, Moiseyenko, V, Demidov, L, Soriano, V, Chmielowska, E, Andrés, R, Kudryavtseva, G, Kahatt, C, Szyldergemajn, S, Extremera, S, de Miguel, B, Cullell-Young, M, Calvert, H

“…Background: This phase I–II trial compared plitidepsin 1-h infusion alone or combined with dacarbazine (DTIC) 1-h infusion as front-line therapy for advanced…”
Get full text

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib by Ascierto, P.A., Lewis, K.D., Di Giacomo, A.M., Demidov, L., Mandalà, M., Bondarenko, I., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Simmons, B., Ye, C., Hooper, G., Wongchenko, M.J., Goodman, G.R., Yan, Y., Schadendorf, D.

“…We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in…”
Get full text

On Multi-Line Spectro-Polarimetric Diagnostics of the Quiet Sun's Magnetic Fields by Demidov, M L, Balthasar, H

“…On the long way to establish reliable physical properties of the solar atmosphere from different kinds of magnetic field measurement, significant progress has…”
Get full text

Somatostatin receptor type 2 expression in Merkel cell carcinoma as a prognostic factor by Orlova, K.V., Delektorskaya, V.V., Vishnevskaya, Y.V., Kondratieva, T.T., Orel, N.F., Markovich, A.A., Demidov, L.V., Subramanian, S.

Get full text

140 Analysis of BRAF/NRAS/KIT mutations and NPM/NCL gene alterations in the cutaneous melanoma samples by Lushnikova, A, Ponkratova, D, Tsyganova, I, Balbutsky, A, Mikhailova, I, Vikhrova, A, Cheremushkin, E, Petenko, N, Demidov, L, Mazurenko, N

Get full text

S30. Management of head & neck melanomas by Subramanian, S, Demidov, L

Get full text

FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma by Tsimafeyeu, I., Khasanova, A., Stepanova, E., Gordiev, M., Khochenkov, D., Naumova, A., Varlamov, I., Snegovoy, A., Demidov, L.

“…Background Up to date, there are no data about FGFR2 expression and its predictive role in papillary RCC (pRCC) patients. The aim of the present study was to…”
Get full text

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study by Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F

“…PurposeThe PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed…”
Get full text

7113 POSTER DISCUSSION FGF-mechanism of Resistance to VEGF Receptor Antagonists by Tsimafeveu, I, Demidov, L, Wynn, N

Get full text

25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study by McArthur, G, Larkin, J, Dréno, B, Ascierto, P, Liszkay, G, Maio, M, Mandal´, M, Demidov, L, Stroyakovskiy, D, Thomas, L, De la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Wongchenko, M, Hsu, J, Koralek, D, Rooney, I, Yan, Y, Ribas, A

Get full text

Approaches to metastatic skin melanoma therapy in 2020: a dynamic way forward by Samoylenko, I. V., Demidov, L. V.

“…The choice of first-line therapy for metastatic skin melanoma has become quite a difficult task in the last few years: a practicing oncologist has got drugs of…”
Get full text

The spectrum of oncogene mutations differs among melanoma subtypes by Mazurenko, N. N., Tsyganova, I. V., Lushnikova, A. A., Ponkratova, D. A., Anurova, O. A., Cheremushkin, E. A., Mikhailova, I. N., Demidov, L. V.

“…Melanoma is the most lethal skin malignancy that comprises clinically relevant molecular subsets defined by specific “driver” mutations in BRAF, NRAS , and KIT…”
Get full text